Charline Lasnon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10666339/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 17-31.	6.4	206
2	Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 985-996.	6.4	107
3	Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy. European Radiology, 2020, 30, 4623-4632.	4.5	61
4	Impact of Point Spread Function Reconstruction on Thoracic Lymph Node Staging With 18F-FDG PET/CT in Non–Small Cell Lung Cancer. Clinical Nuclear Medicine, 2012, 37, 971-976.	1.3	53
5	18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2324-2335.	6.4	45
6	New PET technologies – embracing progress and pushing the limits. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2711-2726.	6.4	35
7	Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction. Annals of Nuclear Medicine, 2017, 31, 125-134.	2.2	33
8	Does PET SUV Harmonization Affect PERCIST Response Classification?. Journal of Nuclear Medicine, 2016, 57, 1699-1706.	5.0	31
9	Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs). EJNMMI Research, 2017, 7, 30.	2.5	27
10	Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 421-428.	6.4	27
11	How fast can we scan patients with modern (digital) PET/CT systems?. European Journal of Radiology, 2020, 129, 109144.	2.6	23
12	The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: focus on the Deauville criteria. Haematologica, 2014, 99, e84-e85.	3.5	22
13	Does PET Reconstruction Method Affect Deauville Score in Lymphoma Patients?. Journal of Nuclear Medicine, 2018, 59, 1049-1055.	5.0	22
14	Assessment of alteration in liver 18F–FDG uptake due to steatosis in lymphoma patients and its impact on the Deauville score. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 941-950.	6.4	16
15	EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program. EJNMMI Physics, 2017, 4, 17.	2.7	14
16	Patient's weight: a neglected cause of variability in SUV measurements? A survey from an EARL accredited PET centre in 513 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 197-199.	6.4	13
17	Revisiting detection of in-transit metastases in melanoma patients using digital 18F-FDG PET/CT with small-voxel reconstruction. Annals of Nuclear Medicine, 2021, 35, 669-679.	2.2	13
18	Advances in PET/CT Technology: An Update. Seminars in Nuclear Medicine, 2022, 52, 286-301.	4.6	12

CHARLINE LASNON

#	Article	IF	CITATIONS
19	Comprehensive analysis of the influence of G-CSF on the biodistribution of 18F-FDG in lymphoma patients: insights for PET/CT scheduling. EJNMMI Research, 2019, 9, 79.	2.5	6
20	Diagnostic value of baseline 18FDG PET/CT skeletal textural features in follicular lymphoma. Scientific Reports, 2021, 11, 23812.	3.3	6
21	Reply to: "All that glitters is not gold – new reconstruction methods using Deauville criteria for patient reporting― European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 878-881.	6.4	5
22	End-of-treatment ¹⁸ F-FDG PET/CT in diffuse large B cell lymphoma patients: ΔSUV outperforms Deauville score. Leukemia and Lymphoma, 2021, 62, 2890-2898.	1.3	4
23	Reply to the Letter to the Editor from Peters et al: On the use of the liver as a reference organ for Deauville scoring in lymphoma patients and how it may be affected by liver steatosis. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2233-2234.	6.4	1
24	18F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital. Diagnostics, 2021, 11, 1198.	2.6	1